Eisai Co (4523) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Eisai Co JP:4523 is currently developing the following drugs: E2086, E6742, E1018, Lecanemab, E2814, E2086, Active Comparator, Bb-1701, Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Keytruda, E7080, Pegylated Liposomal Doxorubicin, Paclitaxel, Topotecan, Morab-202, Lemborexant, Pbo, Morab-202, Pembrolizumab, Lenvatinib, Pembrolizumab, Lenvatinib, E7386, Febuxostat, Dotinurad, E2814, Pembrolizumab, Oxaliplatin, Paclitaxel, Lenvatinib, Cisplatin, Leucovorin, 5-Fu, Levoleucovorin, Pembrolizumab, Paclitaxel, Lenvatinib, Carboplatin, Pembrolizumab, Lenvatinib, Regorafenib, Tas-102, Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Pembrolizumab, Pemetrexed, Lenvatinib, Carboplatin, Cisplatin, Pembrolizumab, Oxaliplatin, Capecitabine, Lenvatinib, 5-Fu, Leucovorin, Belzutifan, Lenvatinib, Cabozantinib, Fulvestrant, Exemestane, E7090, Lorcaserin, H3b-6545, Antihistamine, Lemborexant, Lecanemab, Lenvatinib, Pembrolizumab, Docetaxel, Paclitaxel, Capecitabine, Lenvatinib, Cetuximab, Dexamethasone, Lenvatinib, Prednisone, Prednisolone, Farletuzumab Ecteribulin, Palbociclib, H3b-6545, Tasurgratinib, Pembrolizumab, Tace, Lenvatinib, E7090. These drug candidates are in various stages of clinical development as the company works toward FDA approval.